



Artisan Small Cap Fund

MONTHLY
Commentary

Investor Class: ARTSX | Advisor Class: APDSX

As of 30 June 2024

Commentary

The Russell 2000® Index returned -0.9% in June, bringing the Q2 total to -3.3%. Investors entered the month relieved that US economic activity was not running too hot to allow for easing inflationary pressures, but then the May employment report called the soft-landing scenario into question. 272,000 jobs were added to US payrolls, well above the 190,000 consensus. However, these concerns were alleviated as the month went on due to headline consumer price index data showing consumer prices were unchanged from April to May.

Our portfolio outperformed the Russell 2000® Growth Index in June but trailed in Q2. Among our top detractors were Lattice Semiconductor and Iovance Biotherapeutics. Cyclical pressures continued to impact recent financial results for Lattice. While some areas of the business, such as 5G wireless infrastructure, may take a little while to recover, we believe headwinds in many other areas of the business are set to ease as customers finish selling down elevated inventory levels. During the quarter, sentiment toward the stock was further impacted by the departure of the well-respected CEO. While we were disappointed to see him go, he's taking on an exciting new turnaround challenge, and we believe the company's strategy and operations are on very strong footing.

Iovance Biotherapeutics is a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for cancer patients. The stock rallied significantly in Q1 after the company announced that the FDA approved AMTAGVI™ (lifileucel) for advanced melanoma. However, shares experienced weakness in May after the company reported earnings results. The company announced the enrollment of more than 100 patients for therapy; however, this was not enough to alleviate investor concerns around patient attrition. We view these concerns as overblown and remain invested.

Among our top contributors were Halozyme Therapeutics and Twist Bioscience. Halozyme provides a unique technology platform (ENHANZE®) that allows for the conversion of biologics and small molecule drugs administered intravenously into a subcutaneous formulation. Shares experienced strength due to multiple positive announcements. First, the company announced that argenx (a key partner) received US FDA approval for VYVGART® Hytrulo co-formulated with ENHANZE® for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). And second, it announced that Roche received European Commission marketing authorization for OCREVUS® co-formulated with ENHANZE® for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Twist Bioscience is a life sciences company with a proprietary silicon-based platform for writing DNA. Synthetic biology is used by biotech companies looking to extend drug discovery and development capabilities as well as diagnostics companies developing methods of detecting diseases at earlier stages. Other applications include creating disease-resistant food crops and the creation of biofuels as alternatives to fossil fuels. Synthetic biology is a large and rapidly growing market, and we believe Twist is currently in the pole position. Shares outperformed after the company reported strong earnings results, including growth of 25% for revenues and 48% for orders. We added to the position.

Portfolio Details

	ARTSX	APDSX
Net Asset Value (NAV)	\$33.70	\$34.08
Inception	28 Mar 1995	1 Feb 2017
Expense Ratios		
Semi-Annual Report 31 Mar 2024 ¹	1.22%	1.09%
Prospectus 30 Sep 2023 ²	1.23%	1.07%

¹Unaudited, annualized for the six-month period. ²See prospectus for further details.

Top 10 Holdings (% of total portfolio)

Halozyme Therapeutics Inc (Health Care)	5.8
Guidewire Software Inc (Information Technology)	5.2
Lattice Semiconductor Corp (Information Technology)	4.7
Ascendis Pharma A/S (Health Care)	4.5
Argenx SE (Health Care)	4.4
SPX Technologies Inc (Industrials)	3.7
Twist Bioscience Corp (Health Care)	3.2
Tyler Technologies Inc (Information Technology)	3.0
MACOM Technology Solutions Holdings Inc (Information Technology)	2.9
Novanta Inc (Information Technology)	2.8
TOTAL	40.3%

Source: Artisan Partners/GICS.

Sector Diversification (% of portfolio securities)

	Fund	R2G ¹
Communication Services	0.0	2.0
Consumer Discretionary	10.2	10.4
Consumer Staples	2.4	4.8
Energy	0.0	4.6
Financials	2.0	5.9
Health Care	33.5	21.6
Industrials	12.5	19.9
Information Technology	39.4	24.0
Materials	0.0	4.0
Real Estate	0.0	1.4
Utilities	0.0	1.3
TOTAL	100.0%	100.0%

Source: Artisan Partners/GICS/Russell. Cash and cash equivalents represented 1.8% of the total portfolio. ¹Russell 2000® Growth Index.

Investment Results (%)

As of 30 June 2024	Average Annual Total Returns							
	MTD	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Inception
Investor Class: ARTSX	1.60	-4.45	4.56	5.05	-9.51	4.77	8.93	8.91
Advisor Class: APDSX	1.61	-4.40	4.60	5.19	-9.38	4.91	9.04	8.95
Russell 2000® Growth Index	-0.17	-2.92	4.44	9.14	-4.86	6.17	7.39	7.55
Russell 2000® Index	-0.93	-3.28	1.73	10.06	-2.58	6.94	7.00	8.76

Source: Artisan Partners/Russell. Returns for periods less than one year are not annualized. Class inception: Investor (28 March 1995); Advisor (1 February 2017). For the period prior to inception, Advisor Class performance is the Investor Class's return for that period ("Linked Performance"). Linked Performance has not been restated to reflect expenses of the Advisor Class and the share class's returns during that period would be different if such expenses were reflected.

Past performance does not guarantee and is not a reliable indicator of future results. Investment returns and principal values will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than that shown. Call 800.344.1770 for current to most recent month-end performance.

Market Cap Distribution (% of portfolio securities)

\$ in billions	Fund	R2G ¹
5.9+	71.9	26.3
4.1–5.9	8.3	20.2
2.9–4.1	9.5	17.3
1.8–2.9	6.7	17.7
0.0–1.8	3.6	18.5
TOTAL	100.0%	100.0%

Source: Artisan Partners/Russell. ¹Russell 2000® Growth Index.

Team Leadership (Pictured left to right)



Portfolio Managers	Years of Investment Experience
Craig Cepukenas, CFA (Co-Lead)	35
Jay Warner, CFA (Co-Lead)	22
James Hamel, CFA	27
Jason White, CFA	24
Matthew Kamm, CFA	24

Carefully consider the Fund's investment objective, risks and charges and expenses. This and other important information is contained in the Fund's prospectus and summary prospectus, which can be obtained by calling 800.344.1770. Read carefully before investing.

Current and future portfolio holdings are subject to risk. The value of portfolio securities selected by the investment team may rise or fall in response to company, market, economic, political, regulatory or other news, at times greater than the market or benchmark index. A portfolio's environmental, social and governance ("ESG") considerations may limit the investment opportunities available and, as a result, the portfolio may forgo certain investment opportunities and underperform portfolios that do not consider ESG factors. International investments involve special risks, including currency fluctuation, lower liquidity, different accounting methods and economic and political systems, and higher transaction costs. These risks typically are greater in emerging and less developed markets, including frontier markets. Securities of small- and medium-sized companies tend to have a shorter history of operations, be more volatile and less liquid and may have underperformed securities of large companies during some periods. Growth securities may underperform other asset types during a given period.

Russell 2000® Growth Index measures the performance of US small-cap companies with higher price/book ratios and forecasted growth values. Russell 2000® Index measures the performance of roughly 2,000 US small-cap companies. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the Fund's holdings, securities of the same issuer are aggregated to determine the weight in the Fund. The discussion of portfolio holdings does not constitute a recommendation of any individual security. These holdings comprise the following percentages of the Fund's total net assets as of 30 Jun 2024: lovance Biotherapeutics Inc 1.3%. Securities named in the Commentary, but not listed as a Top Ten Holding or not listed here are not held in the Fund as of the date of this report. The portfolio managers' views and portfolio holdings are subject to change and the Fund disclaims any obligation to advise investors of such changes.

Unless otherwise indicated, all information in this report includes all classes of shares, except performance and expense ratio information, and is as of the date shown in the upper right hand corner. Totals may not sum due to rounding.

This material is provided for informational purposes without regard to your particular investment needs and shall not be construed as investment or tax advice on which you may rely for your investment decisions. Investors should consult their financial and tax adviser before making investments in order to determine the appropriateness of any investment product discussed herein.

The Global Industry Classification Standard (GICS®) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's Financial Services, LLC (S&P). Neither MSCI, S&P, their affiliates, nor any of their third party providers ("GICS Parties") makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including warranties of accuracy, completeness, merchantability and fitness for a particular purpose. The GICS Parties shall not have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of such damages.

Frank Russell Company ("Russell") is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Frank Russell Company. Neither Russell nor its licensors accept any liability for any errors or omissions in the Russell Indexes and/or Russell ratings or underlying data and no party may rely on any Russell Indexes and/or Russell ratings and/or underlying data contained in this communication. No further distribution of Russell Data is permitted without Russell's express written consent. Russell does not promote, sponsor or endorse the content of this communication.

Sector exposure percentages reflect sector designations as currently classified by GICS.

Our capital allocation process is designed to build position size according to our conviction. Portfolio holdings develop through three stages: GardenSM, CropSM and HarvestSM. GardenSM investments are situations where we believe we are right, but there is not clear evidence that the profit cycle has taken hold, so positions are small. CropSM investments are holdings where we have gained conviction in the company's profit cycle, so positions are larger. HarvestSM investments are holdings that have exceeded our estimate of intrinsic value or holdings where there is a deceleration in the company's profit cycle. HarvestSM investments are generally being reduced or sold from the portfolios.

Artisan Partners Funds offered through Artisan Partners Distributors LLC (APDLLC), member FINRA. APDLLC is a wholly owned broker/dealer subsidiary of Artisan Partners Holdings LP. Artisan Partners Limited Partnership, an investment advisory firm and adviser to Artisan Partners Funds, is wholly owned by Artisan Partners Holdings LP.

© 2024 Artisan Partners. All rights reserved.

7/3/2024 A24342L_vR